The TSX Venture Exchange (“TSX.V”) is currently conducting a Listing Review of Xali Gold, which is a normal part of the review process after trading has been halted in a Company. The Company is ...

This assignment extends Bowman’s reach within IDOT and represents the first contract win within Region Two/District Two. Bowman has a strong track record of delivering complex infrastructure projects ...

The new requirements under Article 3.3 of the RED, effective Aug. 1, 2025, introduce a cybersecurity foundation for connected devices sold in the European Union. Energy systems with wireless ...

MONTRÉAL, Aug. 21, 2025 (GLOBE NEWSWIRE) -- GURU Organic Energy Corp. (TSX: GURU) (“ GURU ” or the “ Company ”), Canada’s ...

Vafseo was approved by the U.S. Food and Drug Administration (FDA) in March 2024 for the treatment of anemia due to CKD in adults who have been receiving dialysis for at least three months. The ...

WESTBROOK, Maine, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a leading consumer health and wellness company, is confirmed to present at the 2025 ...

We are honored to be recognized by the U.S. Army through the xTech program and excited to advance to the final pitch,” said Jay Yu , Founder and Chairman of NANO Nuclear. “This milestone underscores ...

“This newly created video partnership marks a pivotal moment for Gray. With this game-changing infrastructure, we are leading the charge into the future of local streaming, one personalized viewing ...

Austin, Texas, Aug. 21, 2025 (GLOBE NEWSWIRE) -- LendFriend Mortgage LLC announced it is now offering crypto-backed mortgage solutions to homebuyers across major U.S. markets. These financing options ...

New non-human primate (NHP) data for VLTR-559, a long-acting anti-VEGF therapy that could reduce the dosing frequency for the treatment of wet ...

Cube Biotech, a pioneer in membrane protein stabilization and purification, and X-Chem, the global leader in DNA-Encoded Library (DEL) technology and data-driven drug discovery, are proud to announce ...

Presentation title : Subretinal gene therapy laru-zova for X-linked retinitis pigmentosa (XLRP): Phase 2 DAWN trial, preliminary month 9+ results Date : Thursday, September 4, 2025 Presenter : Rajiv ...